星空体育注册官网|正牌大公司

You Position: Home > Paper

The epidemic status of mpox and progress towards mpox vaccine research:a literature review

( views:2, downloads:0 )

Author:: No author available

Journal Title:: Chinese Journal of Vaccines and Immunization

Issue:: 2

DOI:: 10.19914/j.CJVI.2024038

Key Word:: 猴痘病毒;猴痘;流行;猴痘疫苗;疫苗研发;Monkeypox virus;Mpox;Epidemics;Mpox vaccine;Vaccine research

Abstract： Mpox(formerly known as monkeypox)has spread widely in some non-endemic areas since May 2022,leading to considerable interest and attention.Since June 2023,many provinces in China reported mpox cases,indicating an increasing risk for local transmission and infection.Vaccination is one of the most important measures for epidemic prevention and control.The World Health Organization recommends three vaccines for mpox prevention in populations at high risk for monkeypox virus infection:ACAM2000,MVA-BN,and LC16.Many vaccines are under development,including attenuated live vaccines,mRNA vaccines,DNA vaccines,and recombinant subunit vaccines.In this article,we provide an overview of the status of mpox epidemics and progress in mpox vaccine research to provide reference for mpox prevention and control strategies and vaccine development in China.

Reference

[1]彭泽旭,刘甦苏,王辰飞,等.复制型天坛株痘苗病毒在免疫缺陷型大鼠体内的生物分布特点及其对组织病理变化的影响[J].2018,(7).
[2]Earl, Patricia L.,Americo, Jeffrey L.,Wyatt, Linda S.,etc.Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.[J].2004,428(6979).
[3]Saito T,Fujii T,Kanatani Y,etc.Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.[J].2009,301(10).
[4]Sergei N. Shchelkunov,Alexei V. Totmenin,Igor V. Babkin,etc.Human monkeypox and smallpox viruses: genomic comparison[J].2001,509(1).
[5]Mbala, Placide K.,Huggins, John W.,Riu-Rovira, Therese,etc.Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo[J].2017,216(7).
[6]S. N. Yakubitskiy,"name":"State Research Center of Virology and Biotechnology \u201cVector\u201d, Koltsovo, Novosibirsk region, Russia,I. V. Kolosova,etc.Attenuation of Vaccinia Virus[J].2019,7(4).
[7]Nigam P,Earl PL,Americo JL,etc.DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge[J].2007,366(1).
[8]Graham J. Hatch,Victoria A. Graham,Kevin R. Bewley,etc.Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques[J].2013,87(14).
[9]Niubing Zhang,Xiang Cheng,Yilong Zhu,etc.Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity[J].2023,(10).
[10]Brett W, Petersen,Inger K, Damon,Carol A, Pertowski,etc.Clinical guidance for smallpox vaccine use in a postevent vaccination program.[J].2015,64(RR-02).
[11]X, Hui,J, Yutu.The eradication of smallpox in Shanghai, China, October 1950-July 1951.[J].1981,59(6).
[12]Hirao LA,Draghia Akli R,Prigge JT,etc.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.[J].2011,203(1).
[13]Earl, PL,Americo, JL,Wyatt, LS,etc.Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus[J].2008,105(31).
[14]Artenstein AW,Johnson C,Marbury TC,etc.A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults[J].2005,23(25).
[15]Rimoin, A.W.,Mulembakani, P.M.,Johnston, S.C.,etc.Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo[J].2010,107(37).
[16]Heraud JM,Edghill Smith Y,Ayala V,etc.Subunit recombinant vaccine protects against monkeypox.[J].2006,177(4).
[17].The prevalence of HIV among MSM in China: a large-scale systematic analysis[J].2019,19(1).
[18]Frey, S. E.,Newman, F. K.,Kennedy, J. S.,etc.Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults[J].2009,27(10).
[19]Pittman, Phillip R.,Hahn, Matthew,Lee, HeeChoon S.,etc.Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox[J].2019,381(20).
[20]Aysegul, Nalca,Elizabeth E, Zumbrun.ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.[J].2010,4.
[21]Andrew T,Russo,Aklile,Berhanu,Catherine B,Bigger,etc.Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.[J].2020,38(3).
[22]I D, Ladnyj,P, Ziegler,E, Kima.A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo.[J].1972,46(5).
[23]Richard N Greenberg,Edgar Turner Overton,David W Haas,etc.Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.[J].2013,207(5).
[24]Walsh, Stephen R.,Wilck, Marissa B.,Dominguez, David J.,etc.Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial[J].2013,207(12).
[25]Randa Elsheikh,Abdelrahman M.Makram,Tamilarasy Vasanthakumaran,etc.Monkeypox:A comprehensive review of a multifaceted virus[J].2023,(2).
[26]Lei Yang,Yingshan Chen,SHA Li,etc.Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus[J].2023,(1).
[27]Sharon E. Frey,Anna Wald,Srilatha Edupuganti,etc.Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects[J].2015,33(39).
[28]Preben von Magnus,Else Krag Andersen,Knud Birkum Petersen,etc.A Pox‐like Disease in Cynomolgus Monkeys[J].1959,46(2).
[29]Hooper JW,Thompson E,Wilhelmsen C,etc.Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox[J].2004,78(9).
[30]Kennedy JS,Gurwith M,Dekker CL,etc.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.[J].2011,204(9).
[31]Yinka-Ogunleye, Adesola,Aruna, Olusola,Dalhat, Mahmood,etc.Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report[J].2019,19(8).
[32]R. A. Maksyutov,"name":"State Research Center of Virology and Biotechnology \u00abVector\u00bb, Koltsovo, Novosibirsk region, 630559, Russia,S. N. Yakubitskyi,etc.Comparing New-Generation Candidate Vaccines against Human Orthopoxvirus Infections[J].2019,9(2).
[33]Meyer H,Stemmler M,Schmitz H,etc.Outbreaks of Disease Suspected of Being Due to Human Monkeypox Virus Infection in the Democratic Republic of Congo in 2001.[J].2002,40(8).
[34]Berhanu, Aklile,Prigge, Jonathan T.,Silvera, Peter M.,etc.Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox Virus Infection[J].2015,59(7).
[35]Yokote, Hiroyuki,Shinmura, Yasuhiko,Kanehara, Tomomi,etc.Safety of Attenuated Smallpox Vaccine LC16m8 in Immunodeficient Mice[J].2014,21(9).
[36].Reemergence of Human Monkeypox in Nigeria, 2017[J].2018,24(6).
[37]Keckler, M. S.,Carroll, D. S.,Gallardo-Romero, N. F.,etc.Establishment of the Black-Tailed Prairie Dog (Cynomys ludovicianus) as a Novel Animal Model for Comparing Smallpox Vaccines Administered Preexposure in both High- and Low-Dose Monkeypox Virus Challenges[J].2011,85(15).
[38]Marriott KA,Parkinson CV,Morefield SI,etc.Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge[J].2008,26(4).
[39]Meisinger-Henschel C,Schmidt M,Lukassen S,etc.Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara[J].2007,88(12).
[40].IMVAMUNE<sup>®</sup> and ACAM2000<sup>®</sup> Provide Different Protection against Disease When Administered Postexposure in an Intranasal Monkeypox Challenge Prairie Dog Model[J].2020,8(396).
[41]Itoe Iizuka,Yasushi Ami,Yuriko Suzaki,etc.A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox[J].2017,70(4).
[42]Wilck MB,Seaman MS,Baden LR,etc.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.[J].2010,201(9).
[43]Y J, Hutin,R J, Williams,P, Malfait,etc.Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.[J].1900,7(3).
[44]D L, Heymann,M, Szczeniowski,K, Esteves.Re-emergence of monkeypox in Africa: a review of the past six years.[J].1998,54.
[45]Frank, von Sonnenburg,Pamela, Perona,Ulf, Darsow,etc.Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.[J].2014,32(43).
[46]Petersen, Eskild,Kantele, Anu,Koopmans, Marion,etc.Human Monkeypox Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention[J].2019,33(4).
[47]P E, Fine,Z, Jezek,B, Grab,etc.The transmission potential of monkeypox virus in human populations.[J].1988,17(3).
[48]Qizan Gong,Changle Wang,Xia Chuai,etc.Monkeypox virus: a re-emergent threat to humans[J].2022,(4).
[49]Edghill Smith Y,Golding H,Manischewitz J,etc.Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.[J].2005,11(7).
[50]Zhenhao Fang,Valter S.Monteiro,Paul A.Renauer,etc.Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens[J].2023,33(5).
[51]Saijo M,Ami Y,Suzaki Y,etc.LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox[J].2006,80(11).
[52]Kenner J,Cameron F,Empig C,etc.LC16m8: an attenuated smallpox vaccine[J].2006,24(47/48).
[53]Stittelaar KJ,van Amerongen G,Kondova I,etc.Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus[J].2005,79(12).
[54]Eto, Akiko,Saito, Tomoya,Yokote, Hiroyuki,etc.Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8[J].2015,33(45).
[55]M. Saijo,Y. Ami,Y. Suzaki,etc.Post-Exposure Vaccination with a Highly Attenuated Vaccinia Vaccine, LC16m8, for Protection of Nonhuman Primates from Monkeypox[J].2008,12(1).